Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)
PHARMASCIENCE INC
N06DA03
RIVASTIGMINE
3.0MG
CAPSULE
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 3.0MG
ORAL
60/100
Prescription
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Active ingredient group (AIG) number: 0140521002; AHFS:
APPROVED
2009-07-20
PRODUCT MONOGRAPH PR PMS-RIVASTIGMINE Rivastigmine Hydrogen Tartrate Capsules, House Standard 1.5 mg, 3 mg, 4.5 mg and 6 mg of Rivastigmine (as Rivastigmine Hydrogen Tartrate) CHOLINESTESTERASE INHIBITOR PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Québec H4P 2T4 Date of Revision : November 1, 2016 www.pharmascience.com SUBMISSION CONTROL NO: 199174 _ _ _pms-RIVASTIGMINE Product Monograph _ _Page 2 of 52_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ...................................................... 3 SUMMARY PRODUCT INFORMATION ..................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................... 3 CONTRAINDICATIONS ............................................................................................... 4 WARNINGS AND PRECAUTIONS .............................................................................. 4 ADVERSE REACTIONS ............................................................................................. 11 DRUG INTERACTIONS .............................................................................................. 23 DOSAGE AND ADMINISTRATION .......................................................................... 24 OVERDOSAGE ........................................................................................................... 26 ACTION AND CLINICAL PHARMACOLOGY ......................................................... 27 STORAGE AND STABILITY ...................................................................................... 29 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................... 29 PART II: SCIENTIFIC INFORMATION ........................................................................... 31 PHARMACEUTICAL INFORMATION ...................................................................... 31 CLINICAL TRIALS .................................................................................................... Կարդացեք ամբողջական փաստաթուղթը